924 related articles for article (PubMed ID: 2963831)
1. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
Gurewich V; Pannell R
Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.
Liu JN; Gurewich V
J Clin Invest; 1991 Dec; 88(6):2012-7. PubMed ID: 1836471
[TBL] [Abstract][Full Text] [Related]
4. Activation of fibrin-bound plasminogen by pro-urokinase and its complementariness with that by tissue plasminogen activator.
Gurewich V
Enzyme; 1988; 40(2-3):97-108. PubMed ID: 2971533
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).
Gurewich V; Pannell R; Broeze RJ; Mao J
J Clin Invest; 1988 Dec; 82(6):1956-62. PubMed ID: 2974047
[TBL] [Abstract][Full Text] [Related]
6. The kinetics of plasminogen activation by thrombin-cleaved pro-urokinase and promotion of its activity by fibrin fragment E-2 and by tissue plasminogen activator.
Liu JN; Gurewich V
Blood; 1993 Feb; 81(4):980-7. PubMed ID: 8428004
[TBL] [Abstract][Full Text] [Related]
7. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
Watahiki Y; Scully MF; Ellis V; Kakkar VV
Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
[TBL] [Abstract][Full Text] [Related]
8. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect.
Pannell R; Gurewich V
Blood; 1986 May; 67(5):1215-23. PubMed ID: 3083889
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments.
Gurewich V; Pannell R
Blood; 1987 Mar; 69(3):769-72. PubMed ID: 2949785
[TBL] [Abstract][Full Text] [Related]
10. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
11. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
Lijnen HR; Dewerchin M; De Cock F; Collen D
Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
[TBL] [Abstract][Full Text] [Related]
12. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
[TBL] [Abstract][Full Text] [Related]
13. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator.
Silva MM; Thelwell C; Williams SC; Longstaff C
J Thromb Haemost; 2012 Nov; 10(11):2354-60. PubMed ID: 22974122
[TBL] [Abstract][Full Text] [Related]
14. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
Gurewich V; Pannell R
Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
[No Abstract] [Full Text] [Related]
15. Comparison of affinities of urokinase and tissue plasminogen activator for fibrin clots.
Homandberg GA; Wai T
Thromb Res; 1989 Aug; 55(4):493-501. PubMed ID: 2510355
[TBL] [Abstract][Full Text] [Related]
16. Clot penetration and fibrin binding of amediplase,a chimeric plasminogen activator (K2 tu-PA).
Rijken DC; Barrett-Bergshoeff MM; Jie AF; Criscuoli M; Sakharov DV
Thromb Haemost; 2004 Jan; 91(1):52-60. PubMed ID: 14691568
[TBL] [Abstract][Full Text] [Related]
17. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
18. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Sabovic M; Lijnen HR; Keber D; Collen D
Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
[TBL] [Abstract][Full Text] [Related]
19. Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis.
Loza JP; Gurewich V; Johnstone M; Pannell R
Thromb Haemost; 1994 Mar; 71(3):347-52. PubMed ID: 8029800
[TBL] [Abstract][Full Text] [Related]
20. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
